We have previously established that SCLC is vulnerable to agents targeting the DNA damage response (DDR) pathway, including inhibitors of PARP and CHK1, and these findings have led to several clinical trials of DDR inhibitors for SCLC. This evidence concerns the gene CHEK1 and small cell lung carcinoma.